TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01529671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension BID
Study: NCT00318149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: 1 dose administered intramuscularly in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: 1 dose administered intramuscularly in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS25
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS50
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS01B
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS01E
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm
Study: NCT04603768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation \& isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week
Study: NCT02798289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal Neurostimulator
Description: Neurostimulation device
Study: NCT04031521

Intervention type: DIAGNOSTIC_TEST
Intervention: Near infrared spectroscopy
Description: NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Near infrared spectroscopy
Description: NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
Study: NCT03047772

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intensive Atorvastatin
Description: Intensive dose of Atorvastatin therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Atorvastatin
Description: Intensive dose of Atorvastatin therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose BMMSC
Description: Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose BMMSC
Description: Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose BMMSC
Description: High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation
Description: Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation
Description: Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study: NCT02667886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Continuous, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Continuous, oral dosing
Study: NCT03461848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYPHP Evelina London Model of care
Description: Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
Study: NCT04485715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI system
Description: The real-time assistance of AI system
Study: NCT01621204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG infusion
Description: IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
Study: NCT02778399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily
Study: NCT02011425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular advancement appliance
Description: mandibular advancement appliance
Study: NCT04011332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care Model
Description: The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
Study: NCT05650944

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemogram
Description: Sysmex XN-1000 hematological analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemogram
Description: Sysmex XN-1000 hematological analyzer
Study: NCT01354392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
Study: NCT00132379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-217620
Description: 10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
Study: NCT00960674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tactile massage
Description: Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
Study: NCT03355105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort
Description: The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
Study: NCT03632629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive cognitive training
Description: Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
Study: NCT03495674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete cycling classes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive information about exercise guidelines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear Fitbit
Study: NCT03355105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort
Description: The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient.
Study: NCT02826525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Investigational product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study: NCT00882921

Intervention type: BIOLOGICAL
Intervention: Idursulfase
Description: Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
Study: NCT04437147

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fibers with vitamins and minerals will be administered for 30 days once a day in sachets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 Billion UFC strains of probiotics
Description: Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 8 Billion UFC strains of probiotics
Description: Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
Study: NCT01756820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-portal Endoscopic Carpal Tunnel Release (Microaire®)
Description: SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knifelight
Description: A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
Study: NCT01007968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03184922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjustable versus fixed suspensory loop femoral side graft fixation
Description: A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustable versus fixed suspensory loop femoral side graft fixation
Description: A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
Study: NCT00049400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Description: BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
Study: NCT02568332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection
Study: NCT01112696

Intervention type: DEVICE
Group type: OTHER
Intervention: Sensor wear
Description: All subjects to wear sensors
Study: NCT02477397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiromax Budesonide/formoterol
Description: 1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diskus Fluticasone/salmeterol
Description: 2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
Study: NCT03997058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular point pressure therapy
Description: Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular point pressure therapy
Description: Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral estazolam medication
Description: The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral estazolam medication
Description: The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
Study: NCT02779595

Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day

Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
Study: NCT02138747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral
Study: NCT03495674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT02138747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Oral
Study: NCT02332018

Intervention type: RADIATION
Intervention: Biplanar x-ray images
Description: biplanar x-ray images with microdose and low-dose protocol

Intervention type: RADIATION
Intervention: Biplanar x-ray images
Description: biplanar x-ray images with microdose and low-dose protocol

Intervention type: RADIATION
Intervention: Biplanar x-ray images
Description: biplanar x-ray images with microdose and low-dose protocol
Study: NCT02703207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure
Description: CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
Study: NCT04440891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS stimulation with X-Torp task
Description: TMS-Stimulation with X-Torp task

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS-Stimulation with MindMotion Go
Description: TMS-Stimulation with MindMotion Go

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS-Sham with X-Torp task
Description: TMS-Sham with X-Torp task

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS-Sham with MindMotion Go
Description: TMS-Sham with MindMotion Go